MARKET

MYOK

MYOK

MyoKardia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.50
+1.32
+2.35%
Closed 16:15 11/20 EST
OPEN
56.01
PREV CLOSE
56.18
HIGH
59.10
LOW
56.01
VOLUME
459.23K
TURNOVER
--
52 WEEK HIGH
63.76
52 WEEK LOW
39.01
MARKET CAP
2.66B
P/E (TTM)
-11.0219
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MYOK and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MYOK News

  • 10 Biggest Price Target Changes For Wednesday
  • Benzinga.11/13 13:33
  • Cantor Fitzgerald Maintains Overweight on MyoKardia, Lowers Price Target to $95
  • Benzinga.11/13 12:17
  • Morgan Stanley Maintains Overweight on MyoKardia, Lowers Price Target to $70
  • Benzinga.11/12 13:26
  • MyoKardia's mavacamten successful in mid-stage HCM study
  • seekingalpha.11/11 19:07

More

Industry

Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About MYOK

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
More

Webull offers Myokardia Inc (MYOK) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.